Shots:
- The US FDA has approved OncoMate MSI Dx Analysis System as a companion diagnostic to identify pts with microsatellite stable endometrial carcinoma
- The OncoMate MSI Dx Analysis System is a PCR-based assay that determines MSI status in tumors to identify pts eligible for treatment with Keytruda (pembrolizumab) & Lenvima (lenvatinib)
- OncoMate MSI Dx Analysis System has also received FDA clearance for identifying colorectal cancer pts for Lynch syndrome testing, & is also approved in China & the EU
Ref: Businesswire | Image: Promega | Press Release
Related News:- Johnson & Johnson MedTech Launches Shockwave Javelin Peripheral IVL Catheter in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
